Background

Anna completed her Bachelor of Biomedical Science (Honours) at the Burnet in 2016, researching crystal methamphetamine use amongst people who inject drugs. In 2019, she completed a Master of Mathematical Sciences (Advanced) at the Australian National University, with a focus on applied mathematics and mathematical modelling of infectious diseases.

Anna now works as a research assistant at Burnet Institute in the Modelling and Biostatistics working group. She works on a variety of mathematical modelling/health economics projects related to injecting drug use and hepatitis C elimination. She intends to continue her career developing mathematical models in public health.

Qualifications

• 2019: Master of Mathematical Sciences (Advanced), The Australian National University, Australia
• 2016: Bachelor of Biomedical Science (Honours), Monash University, Australia
• 2015: Bachelor of Biomedicine, University of Melbourne, Australia

Projects (2)

Current (2)

• 

  COVASIM: Modelling COVID-19

• 

  The elimination of hepatitis C as a global public health threat

Publications (9)

2021 (4)

• Prevalence and correlates of simultaneous, multiple substance injection (co-injection) amongst people who inject drugs in Melbourne, Australia.
  Palmer A, Higgs P, Scott N, Agius P, Maher L, Dietze P
  Addiction. 2021 Apr; 116(4):876-888
• A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison.
  Palmer A, Papaluca T, Stoové M, Winter R, Pedrana A, Hellard M, Wilson D, Thompson A, Scott N; EC Victoria Partnership.
  Int J Drug Policy. 2021 Mar; 94:103203
• Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment.
  Palmer AY, Wilkinson A, Aitken C, Dietze P, Dore GJ, Maher L, Sacks-Davis R, Stoové M, Wilson D, Hellard M, Scott N
  J Gastroenterol Hepatol. 2021 Mar; Epub ahead of print
• Modelling the impact of reducing control measures on the COVID-19 pandemic in a low transmission setting.
  Scott N, Palmer A, Delport D, Abeysuriya R, Stuart R, Kerr CC, Ministry D, Klein D, Sacks-Davis R, Heath K, Hainsworth S, Pedrana A, Stoové M, Wilson D, Hellard ME
  Med J Aust. 2021 Feb; 214(2):79-83

2020 (2)

• Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study.
  Palmer A, Scott N, Dietze P, Higgs P
  Harm Reduct J. 2020 Feb; 17(1):14
• A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment.
  Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, Thompson AJ, Wilson DP, Hellard ME, Scott N
  Int J Drug Policy. 2020 Feb; 76:102633

2019 (1)

• Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs.
  Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade-Nwulia OO, Aspinall E, Hutchinson S, Hellard ME, Sacks-Davis R
  Liver Int. 2019 Dec; 39(12):2244-2260

2018 (1)

• Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study.
  Scott N, Palmer A, Morgan C, Lesi O, Spearman CW, Sonderup M, Hellard M
  Lancet Glob Health. 2018 Jun; 6(6):e659-e667

2017 (1)

• "Just not all ice users do that": investigating perceptions and potential harms of Australia's Ice Destroys Lives campaign in two studies.
  Douglass CH, Early EC, Wright CJC, Palmer A, Higgs P, Quinn B, Dietze PM, Lim MSC
  Harm Reduct J. 2017 Jul; 14(1):45